Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis

Authors

• Dimitra Koumaki Dermatology Department, University Hospital of Heraklion, Crete, Greece
• Vasiliki Koumaki Microbiology Department, Medical School of Athens, Athens , Greece
• George Bertsias Rheumatology Department, University Hospital of Heraklion, Crete, Greece
• Eleni Lagoudaki Pathology Department, University Hospital of Heraklion, Crete, Greece
• George Bertsias Rheumatology Department, University Hospital of Heraklion, Crete, Greece

dkoumaki@yahoo.gr

Keywords

Abstract

Objectives: Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA).
Materials and methods: Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who developed palmoplantar pustulosis (PPP) while being treated with baricitinib.
Results: The patient’s PPP resolved after discontinuation of baricitinib and recurred when this was restarted. Based on causality assessment, it was considered a drug-induced PPP. Conclusion: To the authors’ knowledge, this is the first case of baricitinib-induced PPP.